Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals
作者： Gissette Reyes-Soffer , Henry N. Ginsberg
DOI: 10.1002/9781118387658.CH17
关键词: Blood lipids 、 Very low-density lipoprotein 、 Insulin resistance 、 Medicine 、 Apolipoprotein C2 、 Endocrinology 、 Cholesterylester transfer protein 、 Type 2 Diabetes Mellitus 、 Hypolipidemic Agents 、 Apolipoprotein B 、 Internal medicine
摘要:
sci-hub.se 参考文章(105)
J. E. Hokanson, M. A. Austin, Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. Journal of Cardiovascular Risk. ,vol. 3, pp. 213- 219 ,(1996) , 10.1177/174182679600300214
Angela A Rivellese, Claudia De Natale, Lucrezia Di Marino, Lidia Patti, Ciro Iovine, Silvana Coppola, Stefano Del Prato, Gabriele Riccardi, Giovanni Annuzzi, Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. The Journal of Clinical Endocrinology and Metabolism. ,vol. 89, pp. 2153- 2159 ,(2004) , 10.1210/JC.2003-031764
Alexander Tenenbaum, Michael Motro, Enrique Z Fisman, David Tanne, Valentina Boyko, Solomon Behar, Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome Archives of Internal Medicine. ,vol. 165, pp. 1154- 1160 ,(2005) , 10.1001/ARCHINTE.165.10.1154
Tsuguhito Ota, Constance Gayet, Henry N. Ginsberg, Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents Journal of Clinical Investigation. ,vol. 118, pp. 316- 332 ,(2008) , 10.1172/JCI32752
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. The New England Journal of Medicine. ,vol. 346, pp. 393- 403 ,(2002) , 10.1056/NEJMOA012512
Christopher P Cannon, Eugene Braunwald, Carolyn H McCabe, Daniel J Rader, Jean L Rouleau, Rene Belder, Steven V Joyal, Karen A Hill, Marc A Pfeffer, Allan M Skene, Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine. ,vol. 350, pp. 1495- 1504 ,(2004) , 10.1056/NEJMOA040583
, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials The Lancet. ,vol. 376, pp. 1670- 1681 ,(2010) , 10.1016/S0140-6736(10)61350-5
ACCORD Study Group, None, Effects of combination lipid therapy in type 2 diabetes mellitus. The New England Journal of Medicine. ,vol. 362, pp. 1563- 1574 ,(2010) , 10.1056/NEJMOA1001282
, Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy The New England Journal of Medicine. ,vol. 365, pp. 2255- 2267 ,(2011) , 10.1056/NEJMOA1107579
Christie M. Ballantyne, Anders G. Olsson, Thomas J. Cook, Michele F. Mercuri, Terje R. Pedersen, John Kjekshus, Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S Circulation. ,vol. 104, pp. 3046- 3051 ,(2001) , 10.1161/HC5001.100624